Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis.

Liu JJ, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, Que J, Gadad BS, Trivedi MH, Kelsoe JR, Lu L.

Mol Psychiatry. 2019 Aug 19. doi: 10.1038/s41380-019-0474-5. [Epub ahead of print] Review.

PMID:
31427752
2.

Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.

Czysz AH, South C, Gadad BS, Arning E, Soyombo A, Bottiglieri T, Trivedi MH.

Transl Psychiatry. 2019 Jan 16;9(1):11. doi: 10.1038/s41398-018-0349-6.

3.

Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.

Gadad BS, Raj P, Jha MK, Carmody T, Dozmorov I, Mayes TL, Wakeland EK, Trivedi MH.

Mol Neuropsychiatry. 2018 Jun;4(1):7-19. doi: 10.1159/000487321. Epub 2018 May 3.

4.

Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.

Jha MK, Minhajuddin A, Gadad BS, Trivedi MH.

Int J Neuropsychopharmacol. 2017 Nov 1;20(11):919-927. doi: 10.1093/ijnp/pyx060.

5.

Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.

Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP, Trivedi MH.

J Affect Disord. 2018 Jun;233:3-14. doi: 10.1016/j.jad.2017.07.001. Epub 2017 Jul 5. Review.

6.

Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH.

Brain Behav Immun. 2017 Nov;66:103-110. doi: 10.1016/j.bbi.2017.07.005. Epub 2017 Jul 8.

7.

Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial.

Gadad BS, Jha MK, Grannemann BD, Mayes TL, Trivedi MH.

J Psychiatr Res. 2017 Nov;94:1-6. doi: 10.1016/j.jpsychires.2017.05.012. Epub 2017 May 26.

8.

Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Mayes TL, Rush AJ, Trivedi MH.

Psychoneuroendocrinology. 2017 Apr;78:105-113. doi: 10.1016/j.psyneuen.2017.01.023. Epub 2017 Jan 24.

9.

A Search for Blood Biomarkers for Autism: Peptoids.

Zaman S, Yazdani U, Deng Y, Li W, Gadad BS, Hynan L, Karp D, Roatch N, Schutte C, Nathan Marti C, Hewitson L, German DC.

Sci Rep. 2016 Jan 14;6:19164. doi: 10.1038/srep19164.

10.

Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology.

Gadad BS, Li W, Yazdani U, Grady S, Johnson T, Hammond J, Gunn H, Curtis B, English C, Yutuc V, Ferrier C, Sackett GP, Marti CN, Young K, Hewitson L, German DC.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12498-503. doi: 10.1073/pnas.1500968112. Epub 2015 Sep 28. Erratum in: Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):E6827.

11.

α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.

Berrocal R, Vasquez V, Rao Krs S, Gadad BS, Rao KS.

Mol Neurobiol. 2015;51(3):1417-31. doi: 10.1007/s12035-014-8818-2. Epub 2014 Aug 20. Review.

PMID:
25139280
12.

The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.

Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR, Gadad BS, Li W, German DC.

Exp Neurol. 2013 Dec;250:376-83. doi: 10.1016/j.expneurol.2013.10.014. Epub 2013 Oct 30.

13.

Neuropathology and animal models of autism: genetic and environmental factors.

Gadad BS, Hewitson L, Young KA, German DC.

Autism Res Treat. 2013;2013:731935. doi: 10.1155/2013/731935. Epub 2013 Sep 16. Review.

14.

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Sonsalla PK, Wong LY, Harris SL, Richardson JR, Khobahy I, Li W, Gadad BS, German DC.

Exp Neurol. 2012 Apr;234(2):482-7. doi: 10.1016/j.expneurol.2012.01.022. Epub 2012 Jan 28.

15.

Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson's disease.

Gadad BS, Subramanya PK, Pullabhatla S, Shantharam IS, Rao KS.

Curr Pharm Des. 2012;18(1):76-84.

PMID:
22211690
16.

Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.

Gadad BS, Britton GB, Rao KS.

J Alzheimers Dis. 2011;24 Suppl 2:223-32. doi: 10.3233/JAD-2011-110182. Review.

PMID:
21460436
17.

Effect of fenbendazole on three behavioral tests in male C57BL/6N mice.

Gadad BS, Daher JP, Hutchinson EK, Brayton CF, Dawson TM, Pletnikov MV, Watson J.

J Am Assoc Lab Anim Sci. 2010 Nov;49(6):821-5.

18.

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.

Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.

Supplemental Content

Loading ...
Support Center